Treatment for COVID-19

Phase-Based Progress Estimates
Texas A&M University, College Station, TX
COVID-19+4 More
All Sexes
What conditions do you have?

Study Summary

This study is being done to understand body's response to hybrid home-based and on-site rehabilitation program utilizing individually tailored exercises throughout a total of 18 sessions with 12 of them occurring onsite, in people with and without chronic respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and Obstructive Sleep Apnea (OSA) and in individuals recovered from COVID-19. Exercise training programs vary widely for people with COPD, OSA, and during prolonged recovery from COVID infection. This study will help identify if this program is helpful to address muscle loss and fatigue specifically in populations with and without chronic respiratory diseases.

Eligible Conditions

  • COVID-19
  • Covid19
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Obstructive Sleep Apnea (OSA)
  • Residual Symptoms of COVID 19

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 21 Secondary · Reporting Duration: up to 8 week Exercise Intervention

Week 8
3-day diet diary
6 minute walk test distance by 6 minute walk test
Attention and executive functions measured by Stroop Color-Word Test (SCWT)
Attention and executive functions measured by Trail Making Test (TMT)
Body Composition using Dual Energy X-Ray Absorptiometry Fat
Body Composition using Dual Energy X-Ray Absorptiometry Muscle
Body Composition using Dual Energy X-Ray Absorptiometry bone density
Bone mineral density by BIA
C-reactive protein by Blood Analysis
COPD Assessment Test
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)
Group differences in learning and memory as measured by Controlled Oral Word Association Test (COWAT)
Group differences in learning and memory as measured by Digit Span
Group differences in overall cognitive abilities as measured by Montreal Cognitive Assessment (MoCA)
Group differences in state of mood as measured by the Profile of Mood State (POMS)
Gut function as reported by "The Gastrointestinal Symptom Rating Scale"
Handgrip strength dynamometry by Handgrip Dynamometer
Peak Power and Strength by Keiser Resistance Training Equipment
Physical activity as reported by "Physical Activity Scale for the Elderly
Skeletal muscle strength of leg by Kin-Com
State of mood as measured by the Hospital Anxiety and Depression Scale (HADS)
Week 8
Whole-body protein and amino acid metabolism response to training

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

200 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 8 week exercise intervention

Trial Background

Prof. Marielle PKJ Engelen, PhD
Principal Investigator
Texas A&M University
Closest Location: Texas A&M University · College Station, TX
2017First Recorded Clinical Trial
3 TrialsResearching COVID-19
22 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able to lay in a supine or elevated position for up to 3 hours.
You have obstructive sleep apnea (OSA) and you have a minimum of 5 minutes of sleep per day.
You have 2 weeks post-recovered from laboratory confirmed case of COVID.
You have been fever-free for 24 hours without fever-reducing medications, and it has been 10 days after onset of symptoms.
You are a healthy male or female according to the investigator's or appointed staff's judgment.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.